Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma
Malignant Mesothelioma (MM) is a rare and aggressive form of tumour that affects the lining of the internal organs for which current treatments have not been proven to be very effective. P16(INK4A) tumour suppressor encoding CDKN2A gene is often downregulated in MM. This protein is a cyclin dependen...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489646/ https://www.ncbi.nlm.nih.gov/pubmed/28680533 http://dx.doi.org/10.18632/genesandcancer.138 |
_version_ | 1783246834518458368 |
---|---|
author | Sobhani, Navid Corona, Silvia P. Zanconati, Fabrizio Generali, Daniele |
author_facet | Sobhani, Navid Corona, Silvia P. Zanconati, Fabrizio Generali, Daniele |
author_sort | Sobhani, Navid |
collection | PubMed |
description | Malignant Mesothelioma (MM) is a rare and aggressive form of tumour that affects the lining of the internal organs for which current treatments have not been proven to be very effective. P16(INK4A) tumour suppressor encoding CDKN2A gene is often downregulated in MM. This protein is a cyclin dependent kinase 4 and 6 inhibitor, that normally phosphorylates RB1, which has to be un-phosphorylated in order to block cell-cycle at G1 in normal cells. Adding CDK inhibitor molecules to MM in pre-clinical studies has been proven to restore the normal function of p16(INK4A), blocking thereby MM cell cycle at G1. Future randomised phase III studies with CDK4/6 inhibitors in MM carrying relevant CDK4/6, cyclin D1/3 or p16 aberrations will be warranted. |
format | Online Article Text |
id | pubmed-5489646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-54896462017-07-05 Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma Sobhani, Navid Corona, Silvia P. Zanconati, Fabrizio Generali, Daniele Genes Cancer Research Perspective Malignant Mesothelioma (MM) is a rare and aggressive form of tumour that affects the lining of the internal organs for which current treatments have not been proven to be very effective. P16(INK4A) tumour suppressor encoding CDKN2A gene is often downregulated in MM. This protein is a cyclin dependent kinase 4 and 6 inhibitor, that normally phosphorylates RB1, which has to be un-phosphorylated in order to block cell-cycle at G1 in normal cells. Adding CDK inhibitor molecules to MM in pre-clinical studies has been proven to restore the normal function of p16(INK4A), blocking thereby MM cell cycle at G1. Future randomised phase III studies with CDK4/6 inhibitors in MM carrying relevant CDK4/6, cyclin D1/3 or p16 aberrations will be warranted. Impact Journals LLC 2017-03 /pmc/articles/PMC5489646/ /pubmed/28680533 http://dx.doi.org/10.18632/genesandcancer.138 Text en Copyright: © 2017 Sobhani et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Perspective Sobhani, Navid Corona, Silvia P. Zanconati, Fabrizio Generali, Daniele Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma |
title | Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma |
title_full | Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma |
title_fullStr | Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma |
title_full_unstemmed | Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma |
title_short | Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma |
title_sort | cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma |
topic | Research Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489646/ https://www.ncbi.nlm.nih.gov/pubmed/28680533 http://dx.doi.org/10.18632/genesandcancer.138 |
work_keys_str_mv | AT sobhaninavid cyclindependentkinase4and6inhibitorsasnoveltherapeuticagentsfortargetedtreatmentofmalignantmesothelioma AT coronasilviap cyclindependentkinase4and6inhibitorsasnoveltherapeuticagentsfortargetedtreatmentofmalignantmesothelioma AT zanconatifabrizio cyclindependentkinase4and6inhibitorsasnoveltherapeuticagentsfortargetedtreatmentofmalignantmesothelioma AT generalidaniele cyclindependentkinase4and6inhibitorsasnoveltherapeuticagentsfortargetedtreatmentofmalignantmesothelioma |